ERRATA -- Aitan agreed to pay over $270K of shareholder money to Shaare Zedek Scientific for a license agreement. He issued a PR to that effect on 8/19/21 with the first tranche of $35K due 8/31/21 and the last tranche due May 1, 2022. It was all just another lie. Financial statements show he never paid them a dime.....It is apparent he never intended to...the same as the old pretend patents resulting in the pretend product, Oraltabs..
Yet somehow those trials that never started are now completed and successful and GCAN is going to the moon as a result. How funny. GCAN has no interest in any clinical trials with Shaare Zedek Scientific
News 
Market Data 
Discover 
